UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

ASCO 2025, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), CCTG IND 234 PC_BETS, Carboplatin, DDR alterations.

ASCO 2025 ProstACT Global, phase 3 study of 177Lu-rosptamab + standard of care versus standard of care alone, metastatic castration-resistant prostate cancer (mCRPC).

ASCO 2025 fully automated PSMA PET quantification, overall survival in patients undergoing 177Lu PSMA therapy, PSMA SUVmean, metastatic castrate resistant prostate cancer (mCRPC).

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morris provided a summary of the PSMAfore trial in progress (NCT04689828). This ...

PSMA and Beyond 2025 antibody drug development (ADC) in prostate cancer, ADC program in advance prostate cancer, PSMA expression, ...

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured a PSMA session and a presentation by Dr. Wolfgang Fendler discussing PSMA-PET for overall survival outcome risk stratification of ...